Crafting a Cross-Species, Large Genomic Model
Decoding the Language of Life
Cognit is crafting a cross-cell, cross-species Large Genomic Model (LGM) that enables high-resolution functional genomics through closed-loop, in-silico, gene and cell engineering, redefining the paradigms in genomics research.
Industries Empowered by Cognit to Build on Our AI Platform
The current state of drug discovery is inefficient and expensive. It takes an average of 12 years and $2.6 billion to bring a new drug to market.
This is due in part to the fact that drug discovery is largely a trial-and-error process. Researchers must first identify a target gene, then develop a drug that can modulate that gene's expression. This process is often time-consuming and expensive, and it can be difficult to predict which drugs will be effective.
High-Resolution Genomics: We've transcended traditional views, achieving significant insights into genetic interactions.
Holistic Tumor Analysis: Our integrated approach offers a comprehensive view of tumor biology, predicting behavior with precision.
Targeted Therapies: We're in the process of identifying and validating therapeutic targets with high accuracy.
Combatting Drug Resistance: Our strategies forecast and counteract drug resistance, ensuring sustained efficacy.
Streamlined Drug Development: Efficiency and cost-effectiveness are at the heart of our optimized processes.
Personalized Therapies: Tailoring treatments to individual tumor profiles is now a reality.
Synthetic Lethality: We're in the process of identifying gene combinations for enhanced tumor cell eradication.
Decoding the Genome: Illuminating previously unknown genomic regions, we're broadening our understanding of tumorigenesis.
Safety Assured: Predicting and validating off-target effects, we prioritize patient safety.
Predicting Tumor Evolution: Our tools simulate tumor evolution, keeping us steps ahead.
Revolutionized Clinical Trials: Our data-driven approach is setting new standards for trial success.